ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies

Current Pharmaceutical Design

Volumn 15, Issue 20, 2009, Pages 2272-2281

  Koller, Garrit ^a,b   Schlomann, Uwe ^a   Golfi, Panagiota ^a   Ferdous, Taheera ^a   Naus, Silvia ^c   Bartsch, Jörg W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ADAM8; Asthma; Autocatalysis; Cancer invasion; Cell adhesion; Immuno evasion; Inflammation; Neurodegeneration

Indexed keywords

ADAM PROTEIN; BATIMASTAT; CD23 ANTIGEN; L SELECTIN; METALLOPROTEINASE INHIBITOR; PROTEIN ADAM10; PROTEIN ADAM8; PROTEIN ADAM8 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGIC ASTHMA; AMINO ACID SEQUENCE; AUTOIMMUNITY; BRAIN CANCER; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; DRUG TARGETING; ENCEPHALITIS; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INFLAMMATORY DISEASE; KIDNEY CANCER; LUNG CANCER; NEURITIS; NEUROPROTECTION; NONHUMAN; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; UVEITIS;

ADAM PROTEINS; ANIMALS; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; MICE;

EID: 69249132152     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682361     Document Type: Review

References (54)

1. Yoshida S, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S. Molecular cloning of cDNA encoding MS2 antigen, a novel cell surface antigen strongly expressed in murine monocytic lineage. Int Immunol 1990; 2: 585-91.
2. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): Expression, primary amino acid sequence, and gene location.Genomics 1997; 41: 56-62.
3. Kataoka M, Yoshiyama K, Matsuura K, Hijiya N, Higuchi Y, Yamamoto S. Structure of the murine CD156 gene, characterization of its promoter, and chromosomal location. J Biol Chem 1997; 272: 18209-15.
4. Richens J, Fairclough L, Ghaemmaghami AM, Mahdavi J, Shakib F, Sewell HF. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology 2007; 212: 29-38.
5. Gómez-Gaviro M, Domínguez-Luis M, Canchado J, Calafat J, Janssen H, Lara-Pezzi E, et al. Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding. J Immunol 2007; 178: 8053-63.
6. Johansson MW, Lye MH, Barthel SR, Duffy AK, Annis DS, Mosher DF. Eosinophils adhere to vascular cell adhesion molecule-1 via podosomes. Am J Respir Cell Mol Biol 2004; 31: 413-22.
7. Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW. Tumor necrosis factor (TNF) alpha induces a metalloprotease-disintegrin, ADAM8 (CD 156): Implications for neuronglia interactions during neurodegeneration. J Neurosci 2000; 20: 7964-7971.
8. Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363-70
9. Wildeboer D, Naus S, Sang QX, Bartsch JW, Pagenstecher A. Expression levels and activities of human Metalloproteinase-disintegrins ADAM8 and ADAM19 in primary brain tumors are associated with invasive activity. J Neuropath Exp Neurol 2006; 65: 516-527.
10. Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, et al. ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 2007 11: 1162-74.
11. King NE, Zimmermann N, Pope SM, Fulkerson PC, Nikolaidis NM, Mishra A, et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 2004; 31: 257-65.
12. Matsuno O, Miyazaki E, Nureki S, Ueno T, Kumamoto T, Higuchi Y. Role of ADAM8 in experimental asthma. Immunol Lett 2006; 102: 67-73
13. Mahoney ET, Benton RL, Maddie MA, Whittemore SR, Hagg T. ADAM8 is selectively up-regulated in endothelial cells and is associated with angiogenesis after spinal cord injury in adult mice. J Comp Neurol 2009; 512: 243-55
14. Ainola M, Li TF, Mandelin J, Hukkanen M, Choi SJ, Salo J, et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction Ann Rheum Dis 2009 68: 427-34.
15. Schwettmann L, Wehmeier M, Jokovic D, Aleksandrova K, Brand K, Manns MP, et al. Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. J Hepatol 2008; 49: 243-50.
16. Vrachnis N, Malamitsi-Puchner A, Samoli E, Botsis D, Iliodromiti Z, Baka S, et al. Elevated mid-trimester amniotic fluid ADAM-8 concentrations as a potential risk factor for preterm delivery. J Soc Gynecol Investig 2006; 13: 186-90.
17. Mandelin J, Li TF, Hukkanen MV, Liljeström M, Chen ZK, Santavirta S, et al. Increased expression of a novel osteoclast-stimulating factor, ADAM8, in interface tissue around loosened hip prostheses. J Rheumatol 2003; 30(9): 2033-8.
18. Naus S, Bartsch JW. ADAM proteins as therapeutic targets in loosening of total hip replacement implants? J Rheumatol 2005; 32: 1870-2.
19. Schlomann U, Wildeboer D, Webster A, Antropova O, Zeuschner D, Docherty AJ, et al. The Metalloprotease-Disintegrin ADAM8: Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem 2002; 277: 48210-48219.
20. Hodgkinson CP, Ye S. Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. Biochem Biophys Res Commun 2003; 308: 505-10.
21. Choi SJ, Han JH, Roodman GD. ADAM8: A novel osteoclast stimulating factor. J Bone Miner Res 2001; 16: 814-22.
22. Kim J, Kim H, Lee SJ, Choi YM, Lee SJ, Lee JY. Abundance of ADAM-8,-9,-10,-12,-15 and -17 and ADAMTS-1 in mouse uterus during the oestrous cycle. Reprod Fertil Dev 2005; 17: 543-555
23. Sriraman V, Eichenlaub-Ritter U, Bartsch JW, Rittger A, Mulders SM, Richards JS. Regulated expression of a disintegrin and metalloprotease 8 (ADAM8) in the ovary: Evidence for a regulatory role of luteinizing hormone and progesterone receptor. Biol Reprod 2008; 78(6): 1038-48
24. Kelly K, Hutchinson G, Nebenius-Oosthuizen D, Smith AJ, Bartsch JW, Horiuchi K, et al. Metalloprotease-Disintegrin ADAM8: Expression analysis and targeted deletion in mice. Dev Dyn 2005; 232: 221-231
25. Howard L, Maciewicz RA, Blobel CP. Cloning and characterization of ADAM28: Evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem J 2000; 348: 21-7.
26. Takeda S, Igarashi T, Mori H, Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 2006; 25: 2388-96.
27. Bridges LC, Hanson KR, Tani PH, Mather T, Bowditch RD. Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain. Biochemistry 2003; 42: 3734-41.
28. Hall T, Leone JW, Wiese JF, Griggs DW, Pegg LE, Pauley AM, et al. Autoactivation of human ADAM8: A novel pre-processing step is required for catalytic activity. Biosci Rep 2008; [Epub ahead of print].
29. Fourie AM, Coles F, Moreno V, Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003; 278: 30469-77.
30. Schluesener HJ. The disintegrin domain of ADAM 8 enhances protection against rat experimental autoimmune encephalomyelitis, neuritis and uveitis by a polyvalent autoantigen vaccine. J Neuro-immunol 1998; 87: 197-202
31. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-89.
32. Naus S, Richter M, Wildeboer D, Schachner M, Moss M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 2004; 279: 16083-90.
33. Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knäuper V, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524: 154-8.
34. Naus S, Reipschläger S, Wildeboer D, Lichtenthaler S, Moss M, Bartsch JW. Identification of novel substrates for the Metalloprotease-Disintegrin ADAM8. Biol Chem 2006; 387: 337-346.
35. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994; 76: 301-14.
36. Walcheck B, Kahn J, Fisher JM, Wang BB, Fisk RS, Payan DG, et al. Neutrophil rolling altered by inhibition of L-selectin shedding in vitro. Nature 1996; 380: 720-3.
37. Smalley DM, Ley K. L-selectin: Mechanisms and physiological significance of ectodomain cleavage. J Cell Mol Med 2005; 9: 255-66.
38. Friedl P, Wolf K. Proteolytic interstitial cell migration: A five-step process. Cancer Metastasis Rev 2009 Jan 21. [Epub ahead of print]
39. Murphy G. The ADAMs: Signalling scissors in the tumour micro-environment Nat Rev Cancer 2008; 8: 929-941.
40. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98: 621-8.
41. Fritzsche FR, Jung M, Xu C, Rabien A, Schicktanz H, Stephan C, et al. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.Virchows Arch 2006; 449: 628-36
42. Foley SC, Mogas AK, Olivenstein R, Fiset PO, Chakir J, Bourbeau J, et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J Allergy Clin Immunol 2007 119: 863-71
43. Huang J, Chen F, Wu Y, Yang J. Expression and clinical significance of ADAM8 and CEA in serum of patients with non-small cell lung cancer. Chin J Lung Cancer 2008; 11: 786-92.
44. Matsuno O, Miyazaki E, Nureki S, Ueno T, Ando M, Ito K, et al. Elevated soluble ADAM8 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 2007; 142: 285-90.
45. Moss ML, Rasmussen FH. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem 2007; 366: 144-8.
46. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008; 8: 205-217.
47. Higuchi Y, Yasui A, Matsuura K, Yamamoto S. CD156 transgenic mice. Different responses between inflammatory types. Pathobiology 2002; 70: 47-54.
48. Paulissen G, Rocks N, Quesada-Calvo F, Gosset P, Foidart JM, Noel A, et al. Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol Med 2006; 12: 171-9.
49. Moss ML, Bartsch JW. Therapeutic benefits from targeting of ADAM family members. Biochemistry 2004 43(23): 7227-35.
50. Tremblay K, Lemire M, Potvin C, Tremblay A, Hunninghake GM, Raby BA, et al. Genes to diseases (G2D) computational method to identify asthma candidate genes. PLoS ONE 2008; 3: E2907.
51. Gonzales PE, Solomon A, Miller AB, Leesnitzer MA, Sagi I, Milla ME. Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain. J Biol Chem 2004; 279: 31638-45.
52. Moss ML, Bomar M, Liu Q, Brown GA, Adam L, Sage H, et al. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits tumor cell proliferation. J Biol Chem 2007; 282: 35712-21.
53. Zigrino P, Steiger J, Fox JW, Löffek S, Schild A, Nischt R, et al. Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J Biol Chem 2007 282(42): 30785-93.
54. Roemer A, Schwettmann L, Jung M, Roigas J, Kristiansen G, Schnorr D, et al. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep 2004; 11: 529-36.